Mixtard 30 Flexpen (Insulin Human)

Mixtard 30 Flexpen, an insulin preparation, is used to manage hyperglycemia in diabetes mellitus.

• Type 1 diabetes mellitus: provides basal insulin to maintain fasting and between‑meal glucose levels.
• Type 2 diabetes mellitus: added when oral agents are insufficient to achieve glycemic targets.
• Gestational diabetes mellitus: may be prescribed when insulin therapy is required during pregnancy.

• Insulin human binds to insulin receptors on muscle, adipose and hepatic cells, activating the intrinsic tyrosine kinase pathway. This promotes translocation of GLUT‑4 transporters, increasing glucose uptake, while suppressing hepatic gluconeogenesis and glycogenolysis. Insulin signaling also enhances protein synthesis and inhibits lipolysis, contributing to overall metabolic homeostasis.

Insulin human may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Hypoglycemia: low blood glucose episodes, especially if dose mismatched with food intake.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Lipodystrophy: localized fat accumulation or loss under the skin.
• Weight gain: increase in body weight due to improved glucose utilization.

Serious or Rare Side Effects

• Allergic reactions: urticaria, angioedema, or anaphylaxis.
• Severe hypoglycemia: seizures or loss of consciousness.
• Edema: peripheral swelling due to fluid retention.
• Insulin antibody formation: may alter insulin action.

When using Mixtard 30 Flexpen, several precautions should be observed to ensure safe and effective therapy.

• Dose adjustment: modify insulin dose based on blood glucose monitoring, diet, and activity levels.
• Hypoglycemia risk: educate patients on recognizing and treating low blood glucose promptly.
• Renal or hepatic impairment: monitor and possibly reduce dose in patients with organ dysfunction.
• Pregnancy and lactation: use only if benefits outweigh potential risks; insulin is category B.
• Concomitant medications: review other drugs that may affect glucose control.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the pen.

Insulin human can interact with other medicines, influencing its glucose‑lowering effect or increasing adverse event risk.

Major Interactions (Avoid)

• Beta‑blockers: may mask hypoglycemia symptoms and prolong insulin action.
• MAO‑A inhibitors: can potentiate insulin’s hypoglycemic effect.

Moderate Interactions (Monitor Closely)

• Oral hypoglycemics (e.g., sulfonylureas, meglitinides): additive glucose‑lowering effect, requiring dose adjustments.
• Corticosteroids: may increase insulin resistance, necessitating higher insulin doses.
• Diuretics (thiazides): can raise blood glucose levels, potentially reducing insulin efficacy.